Janney Montgomery Scott LLC Has $60.53 Million Holdings in Pfizer, Inc. (PFE)
Janney Montgomery Scott LLC boosted its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,801,901 shares of the biopharmaceutical company’s stock after buying an additional 979 shares during the period. Pfizer makes up approximately 0.8% of Janney Montgomery Scott LLC’s investment portfolio, making the stock its 18th largest position. Janney Montgomery Scott LLC’s holdings in Pfizer were worth $60,526,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in PFE. Asset Planning Services Ltd. lifted its holdings in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 137 shares during the last quarter. D. Scott Neal Inc. lifted its holdings in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new position in shares of Pfizer in the first quarter worth about $121,000. Cascade Investment Advisors Inc. lifted its holdings in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 2,200 shares during the last quarter. Finally, Patten Group Inc. lifted its holdings in shares of Pfizer by 5.1% in the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 252 shares during the last quarter. Hedge funds and other institutional investors own 68.98% of the company’s stock.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock valued at $15,813,961 in the last quarter. Corporate insiders own 0.06% of the company’s stock.
A number of research analysts have recently commented on PFE shares. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. UBS AG reissued a “buy” rating and issued a $38.00 target price on shares of Pfizer in a report on Monday, July 31st. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 17th. BMO Capital Markets reissued a “buy” rating and issued a $37.00 target price on shares of Pfizer in a report on Wednesday, September 6th. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $38.15.
Pfizer, Inc. (NYSE PFE) opened at 36.20 on Wednesday. The company has a market cap of $215.29 billion, a price-to-earnings ratio of 26.48 and a beta of 1.00. Pfizer, Inc. has a one year low of $29.83 and a one year high of $36.60. The company has a 50-day moving average of $35.25 and a 200-day moving average of $33.76.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the company posted $0.64 EPS. Pfizer’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities research analysts expect that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.54%. Pfizer’s payout ratio is currently 94.12%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.